- Specialized HD and ALS Patient-Centered Residential Care
Improving Quality of Life for Individuals with Huntington’s Disease and ALS
Each year in the United States, some 2,000 people are diagnosed with Huntington’s Disease, and more than 5,000 are diagnosed with ALS, or amyotrophic lateral sclerosis. Approximately 30,000 Americans are currently living with HD,** and 15 new individuals are diagnosed with ALS each day. These neurodegenerative diseases cannot be cured, which leads to the demand for patient-centered care from skilled health care professionals. Our program is the first of its kind in Upstate New York, providing comprehensive care from onset through the progression of the disease for these residents.
Sitrin NeuroCare Provides
Our highly trained staff of health care professionals understand our residents’ needs and gives them the quality healthcare they require.
Our unit focuses on patient-centered care by providing individualized long-term care plans for each resident, specific to Huntington’s Disease and ALS.
Our residents need an outlet as they face these terminal diseases. We offer HD and ALS support groups for residents, along with caregiver support groups and family support services for those who have a loved one diagnosed with HD or diagnosed with ALS.
We provide nutritional supervision from specially trained and licensed registered dietitians and speech pathologists to ensure residents’ needs are consistently met, especially for those with Huntington’s Disease who may need up to 6,000 calories daily due to energy expended through uncontrolled movements.
Our therapeutic recreation program consists of age-appropriate programs, such as art, music, dance and horticulture.
Our residents receive on-site dental services to address any issues that may require frequent or specialized treatment.
Room modifications and technology are available based on residents’ needs.
There are guest rooms available on our campus for families visiting from longer distances.
Update from Marc DePerno, Outreach Coordinator, Sitrin NeuroCareRead More...
Today is an exciting day for the Huntington’s disease community. The Phase 1/2a Study of IONIS-HTTRx, the first therapy in clinica...Read More...